Aurobindo Pharma climbs on USFDA nod

Aurobindo Pharma climbed on Friday after it has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Amlodipine Besylate and Benazeprilo Hydrochloride Capsules. Amlodipine Besylate and Benazeprilo Hydrochloride Capsules are the generic bioequivalent to the reference listed drug Lotrel Capsules of Novartis Pharmaceuticals Corp. Shares ofthe companyare trading at Rs 123.30, up Rs 4, or 3.35% at the Bombay Stock Exchange (BSE) on Friday at 12:01 p.m.The scrip has touched an intra-day high of Rs 123.70 and low of Rs 119.50. The total volume of shares traded at the BSE is 270,484.In the earlier session, the shares gained 2.58%, or Rs 3, at Rs 119.30. Currently, the stock is trading down 14.55% from its 52-week high of Rs 144.30 and above 53.45% over the 52-week low of Rs 80.35.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 110.70 8.60 7.77 1 Month 110.35 8.95 8.11 3 Months 106.45 12.85 12.07 6 Months 115.10 4.20 3.65 1 Year 136.25 (16.95) (12.44) Note: Based on previous day closing price.